Filing Flows › Companies › Immucell › Report card
Immucell earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate2 of 3 reports beat the EPS estimate
Immucell (ICCC) beat the analysts' EPS estimate in 2 of its last 3 reports (67%), by +20.0% on average. Next report: Nov 12, 2026.
Beat rate67% of 3
Average surprise+20.0%
Next reportNov 12, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise |
|---|---|---|---|---|
| Q to Dec 2020 | Feb 22, 2021 | −$0.04 | $0.03 | n/m |
| Q to Sep 2020 | Nov 12, 2020 | −$0.08 | −$0.04 | +50.0% |
| Q to Jun 2020 | Aug 12, 2020 | −$0.10 | −$0.11 | -10.0% |
Estimates and reported EPS are the Street's adjusted figures. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Immucell: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.